Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/176835
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPellicé, Martina-
dc.contributor.authorRodríguez Núñez, Olga-
dc.contributor.authorRico, Verónica-
dc.contributor.authorAgüero, Daiana-
dc.contributor.authorMorata, Laura-
dc.contributor.authorCardozo Espinola, Celia-
dc.contributor.authorPuerta Alcalde, Pedro-
dc.contributor.authorGarcia Vidal, Carolina-
dc.contributor.authorRubio, Elisa-
dc.contributor.authorFernández Pittol, Mariana José-
dc.contributor.authorVergara Gómez, Andrea-
dc.contributor.authorPitart, Cristina-
dc.contributor.authorMarco Reverté, Francesc-
dc.contributor.authorSantana, Gemina-
dc.contributor.authorRodríguez Serna, Laura-
dc.contributor.authorVilella i Morató, Anna-
dc.contributor.authorLópez, Ester-
dc.contributor.authorSoriano Viladomiu, Alex-
dc.contributor.authorMartínez, José Antonio (Martínez Martínez)-
dc.contributor.authorDel Rio, Ana-
dc.date.accessioned2021-04-28T10:15:12Z-
dc.date.available2021-04-28T10:15:12Z-
dc.date.issued2021-02-01-
dc.identifier.issn1664-302X-
dc.identifier.urihttp://hdl.handle.net/2445/176835-
dc.description.abstractBackground: KPC-producing Klebsiella pneumoniae (KPCKP) is a threat for patients admitted to healthcare institutions. Objectives: To assess the efficacy of several decolonization strategies for KPCKP rectal carriage. Methods: Observational study performed in a 750-bed university center from July to October 2018 on the efficacy of a 10-day non-absorbable oral antibiotic (NAA) regimen (colistin 10 mg/ml, amikacin 8 mg/ml, and nystatin 30 mg/ml, 10 ml/6 h) vs. the same regimen followed by a probiotic (Vivomixx®) for 20 days in adult patients with KPCKP rectal colonization acquired during an outbreak. Results: Seventy-three patients colonized by KPCKP were included, of which 21 (29%) did not receive any treatment and 52 (71.2%) received NAA either alone (n = 26, 35.6%) or followed by a probiotic (n = 26, 35.6%). Eradication was observed in 56 (76.7%) patients and the only variable significantly associated with it was not receiving systemic antibiotics after diagnosis of rectal carriage [22/24 (91.6%) vs. 34/49 (69.3%), p = 0.04]. Eradication in patients receiving NAA plus probiotic was numerically but not significantly higher than that of controls [23/26 (88.4%) vs. 15/21 (71.4%), p = 0.14] and of those receiving only NAA (OR = 3.4, 95% CI = 0.78-14.7, p = 0.09). Conclusion: In an outbreak setting, rectal carriage of KPCKP persisted after a mean of 36 days in about one quarter of patients. The only factor associated with eradication was not receiving systemic antibiotic after diagnosis. A 10-day course of NAA had no impact on eradication. Probiotics after NAA may increase the decolonization rate, hence deserving further study.-
dc.format.extent7 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherFrontiers Media-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fmicb.2021.630826-
dc.relation.ispartofFrontiers in Microbiology, 2021, vol. 12, num. 630826-
dc.relation.urihttps://doi.org/10.3389/fmicb.2021.630826-
dc.rightscc-by (c) Pellicé, Martina et al., 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Fonaments Clínics)-
dc.subject.classificationKlebsiella pneumoniae-
dc.subject.classificationFarmacologia-
dc.subject.otherKlebsiella pneumoniae-
dc.subject.otherPharmacology-
dc.titleFactors Associated With Short-Term Eradication of Rectal Colonization by KPC-2 Producing Klebsiella pneumoniae in an Outbreak Setting-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec710599-
dc.date.updated2021-04-28T10:15:12Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid33597942-
Appears in Collections:Articles publicats en revistes (Fonaments Clínics)

Files in This Item:
File Description SizeFormat 
710599.pdf784.68 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons